Welcome to our dedicated page for Mink Therapeutics SEC filings (Ticker: INKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings rarely read like light bedtime material, and MiNK Therapeutics’ disclosures are no exception. Between pages of iNKT cell science, detailed R&D expense tables, and risk factors on manufacturing scale-up, investors can struggle to pinpoint what really moves the stock. That’s why our MiNK Therapeutics SEC filings page focuses on clarity first.
Stock Titan’s AI parses every 10-K annual report, 10-Q quarterly earnings report, and 8-K material event the moment MiNK submits them to EDGAR. Curious about a capital raise noted after market close? The “MiNK Therapeutics 8-K material events explained” summary highlights terms in plain English. Want to monitor leadership moves? Real-time alerts surface “MiNK Therapeutics Form 4 insider transactions,” letting you track executive stock purchases or sales as they post. Our engine even stitches together complex sections—so “understanding MiNK Therapeutics SEC documents with AI” becomes a five-minute task, not a weekend project.
Use the page to:
- Compare R&D spend trends across each MiNK Therapeutics quarterly earnings report 10-Q filing and see cash runway projections.
- Spot patterns in “MiNK Therapeutics insider trading Form 4 transactions” before key clinical milestones.
- Review the “MiNK Therapeutics proxy statement executive compensation” for option grants tied to trial success.
- Dive into “MiNK Therapeutics annual report 10-K simplified” sections on manufacturing scale and patent estate.
Whether you need a quick “MiNK Therapeutics earnings report filing analysis” or full document downloads, our comprehensive, real-time hub lets you move from data to decisions with confidence.
MiNK Therapeutics, Inc. (NASDAQ: INKT) filed a Form 8-K summarizing the results of its Annual Meeting of Stockholders held on 18 June 2025. A quorum was achieved with 2,793,022 shares (70.41% of outstanding) present in person or by proxy. Shareholders voted on three routine proposals outlined in the proxy dated 30 April 2025.
Proposal 1 – Election of Class I Directors: Incumbents Jennifer Buell and Ulf Wiinberg were each re-elected to serve until the 2028 meeting. Support levels were strong, with Buell receiving 2,337,073 “For” votes (98.7% of votes cast, excluding non-votes) and Wiinberg receiving 2,312,077 “For” votes (97.7%). Broker non-votes totaled 424,803 shares.
Proposal 2 – Option Exchange: Shareholders approved the company’s option exchange program, designed to allow eligible employees to exchange existing stock options for new options. The measure passed with 2,269,364 “For”, 97,538 “Against,” and 1,317 “Abstain,” while 424,803 broker non-votes were recorded.
Proposal 3 – Auditor Ratification: KPMG LLP was ratified as independent registered public accounting firm for fiscal 2025, receiving 2,773,188 “For” votes (99.1%), 12,846 “Against,” and 6,988 abstentions.
No other matters were brought before the meeting, and there were no disclosures regarding financial performance, strategic transactions, or changes in control. The filing is primarily procedural, confirming continued shareholder support for existing leadership and governance practices.
FAQ
What is the current stock price of Mink Therapeutics (INKT)?
What is the market cap of Mink Therapeutics (INKT)?
What is the primary focus of MiNK Therapeutics?
How does MiNK Therapeutics generate its revenue?
What differentiates MiNK Therapeutics from other biopharmaceutical companies?
What are the key products or treatment areas being developed?
What is the significance of scalable manufacturing for the company?
Has MiNK Therapeutics engaged in any strategic collaborations?
How does MiNK Therapeutics address the challenges of treating cancer?
What should investors know about MiNK Therapeutics' clinical trials?
